Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Pooled peripheral blood mononuclear cells provide an optimized cellular substrate for human immunodeficiency virus Type 1 isolation during acute infection.

Lai-Hipp C, Goldberg T, Scott E, Ziman A, Vyas G.

Transfusion. 2011 Feb;51(2):333-7. doi: 10.1111/j.1537-2995.2010.02831.x. Epub 2010 Aug 26.

PMID:
20796251
2.

Isolation and propagation of HIV-1 on peripheral blood mononuclear cells.

van 't Wout AB, Schuitemaker H, Kootstra NA.

Nat Protoc. 2008;3(3):363-70. doi: 10.1038/nprot.2008.3.

PMID:
18323807
3.

A hollow-fiber bioreactor for expanding HIV-1 in human lymphocytes used in preparing an inactivated vaccine candidate.

Leong M, Babbitt W, Vyas G.

Biologicals. 2007 Oct;35(4):227-33. Epub 2007 Aug 28.

PMID:
17728144
4.

L-2-oxothiazolidine-4-carboxylic acid (procysteine) inhibits expression of the human immunodeficiency virus and expression of the interleukin-2 receptor alpha chain.

Lederman MM, Georges D, Dando S, Schmelzer R, Averill L, Goldberg D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Feb 1;8(2):107-15.

PMID:
7834394
5.

Marked differences in quantity of infectious human immunodeficiency virus type 1 detected in persons with controlled plasma viremia by a simple enhanced culture method.

Tremblay CL, Giguel F, Merrill DP, Wong JT, Rosenberg E, Kalams S, Walker BD, D'Aquila RT, Hirsch MS.

J Clin Microbiol. 2000 Nov;38(11):4246-8.

6.

Isolation and characterization of a monoclonal antibody that inhibits HIV-1 infection.

Fu DX, Jinno A, Shimizu N, Haraguchi Y, Hoshino H.

Microbes Infect. 1999 Jul;1(9):677-84.

PMID:
10611745
8.

Human immunodeficiency virus type 1 modulates telomerase activity in peripheral blood lymphocytes.

Ballon G, Ometto L, Righetti E, Cattelan AM, Masiero S, Zanchetta M, Chieco-Bianchi L, De Rossi A.

J Infect Dis. 2001 Feb 1;183(3):417-24. Epub 2000 Dec 18.

9.

Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes.

Cameron PU, Handley AJ, Baylis DC, Solomon AE, Bernard N, Purcell DF, Lewin SR.

J Virol. 2007 Mar;81(5):2297-306. Epub 2006 Dec 13.

10.

Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Bahr GM, Darcissac EC, Castéran N, Amiel C, Cocude C, Truong MJ, Dewulf J, Capron A, Mouton Y.

J Virol. 2001 Aug;75(15):6941-52.

11.

Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects.

Eyeson J, King D, Boaz MJ, Sefia E, Tomkins S, Waters A, Easterbrook PJ, Vyakarnam A.

AIDS. 2003 Nov 7;17(16):2299-311.

PMID:
14571181
13.

R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Gondois-Rey F, Biancotto A, Fernandez MA, Bettendroffer L, Blazkova J, Trejbalova K, Pion M, Hirsch I.

J Virol. 2006 Jan;80(2):854-65.

14.

Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.

Locher CP, Witt SA, Kassel R, Dowell NL, Fujimura S, Levy JA.

J Gen Virol. 2005 Apr;86(Pt 4):1171-9.

PMID:
15784911
19.
20.

Anti-CD4 cytotoxic T lymphocyte (CTL) activity in HIV+ patients: flow cytometric analysis.

Yamamura Y, Rodriguez N, Schwartz A, Eylar E, Yano N.

Cell Mol Biol (Noisy-le-grand). 1995;41 Suppl 1:S133-44.

PMID:
8574141
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk